Check-Cap Ltd. (CHEK)

Nasdaq-listed AI company gains overwhelming shareholder support for its transformational merger, positioning MBody AI ($CHEK) as a hardware-agnostic embodied intelligence leader ready to scale enterprise automation. Las Vegas, Nevada and Isfiya, Isreal--(Newsfile Corp. - November 17, 2025) - MBody AI Corp. ("MBody AI") and Check-Cap Ltd.

MBody AI ($CHEK) continues scaling its hardware-agnostic MBody AI Orchestrator(TM) platform across global enterprise deployments. Las Vegas, Nevada and Isfiya, Isreal--(Newsfile Corp. - November 10, 2025) - MBody AI, a market leader in embodied artificial intelligence, and Check-Cap Ltd.

Shareholders gain exclusive early access to a market-leading embodied AI company driving global growth, innovation, and long-term value creation. Isfiya, Israel--(Newsfile Corp. - November 6, 2025) - Check-Cap Ltd.

Company Has Suspended Calls Since the Second Quarter of 2024 to Avoid Facing the Music for Board's and Management Team's Destruction of 99% of Stock's Value, Costing Shareholders $1 Billion  Conference Call is a Blatant, Self-Serving Reaction by a Management Team Running Scared Following Apollo Capital's Intention to Nominate Six Highly Qualified Directors to MediPharm's Board  Shareholders Deserve Answers From Management About Massive Underperformance, Failed Operational Strategies, Poor Capital Allocation, Outrageous Compensation, and Lack of Transparency Apollo Capital's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Execute Plan to Restore Value for ALL MediPharm Shareholders Urges MediPharm Shareholders to Vote for Wholesale Change at Annual Meeting TORONTO , May 14, 2025 /PRNewswire/ -- Apollo Technology Capital Corporation ("Apollo Capital"), which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs", or the "Company"), owning approximately 3.0% of the Company's common stock, today posed several critical questions that shareholders should ask MediPharm management on this morning's conference call following its first quarter 2025 earnings report. CEO David Pidduck and his management team have not held a call with shareholders since the second quarter of 2024 to avoid having to defend themselves after destroying 99% of the value of the company's stock, or nearly $1 billion.

TORONTO , May 13, 2025 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, has filed its Management Information Circular ("MIC" or the "Circular") and proxy materials (the "Meeting Materials") for its upcoming Annual and Special Meeting of Shareholders, scheduled for June 16, 2025. The Meeting Materials will be sent to shareholders in the coming days, and are available on the SEDAR+ website at www.sedarplus.ca.

Believes Board Change is Urgently Needed: Under the Current Board and Management, MediPharm Stock Price is Down More Than 99%, Costing Shareholders Nearly $1 Billion MediPharm's Board Cannot be Trusted to Create Shareholder Value or Oversee Management! Company Leadership Lacks Any Credible Strategic Plan and Has Made Numerous Reckless Acquisitions While Rewarding Themselves with Excessive Compensation for Repeated Failures Apollo's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Execute Plan to Restore Value for ALL MediPharm Shareholders Urges MediPharm Shareholders to Vote for Wholesale Change at Annual Meeting Sends Letter to MediPharm Shareholders and Files Proxy Circular TORONTO, ON , May 8, 2025 /PRNewswire/ -- Apollo Technology Capital Corporation ("Apollo"), which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs", or the "Company"), owning approximately 3.0% of the Company's common stock, today filed a dissident information proxy circular (the "Circular") in connection with its intention to nominate six highly qualified director candidates to MediPharm's Board of Directors (the "Board") at the Company's upcoming 2025 Annual and Special Meeting of Shareholders to be held on June 10, 2025 (the "Annual Meeting").

Check-Cap (NASDAQ: CHEK ) stock is on the rise Tuesday as the clinical stage medical diagnostics company announces a business combination with Nobul AI . This deal will have Check-Cap hand of the reigns of the company to Nobul AI's leadership team and shareholders.

Proposed business combination to create a North American technology company with an AI-driven fintech marketplace. Combined company to apply for listing on Nasdaq and TSX TORONTO , March 25, 2024 /PRNewswire/ -- Nobul AI Corp. ("Nobul") and Check-Cap Ltd.

TORONTO , Dec. 22, 2023 /PRNewswire/ - Symetryx Corporation ("Symetryx"), a Canadian venture company, is pleased to announce that the shareholders of Check-Cap Ltd. (NASDAQ: CHEK) voted overwhelmingly to elect all the director nominees proposed by Symetryx at the Annual General Meeting held on December 18 th  2023.

SYMETRYX RECOMMENDS VOTING AGAINST THE KEYSTONE DENTAL MERGER SYMETRYX RECOMMENDS VOTING FOR THEIR QUALIFIED INDEPENDENT BOARD NOMINEES TIME IS SHORT - THE VOTE DEADLINE IS 11:59 pm EST THURSDAY DECEMBER 14 th 2023 - SHAREHOLDERS MAY VOTE OR CHANGE A PREVIOUSLY CAST VOTE UNTIL THAT TIME TORONTO , Dec. 13, 2023 /PRNewswire/ - Further to its news release of November 28, 2023, Symetryx continues to urge its fellow Check-Cap Ltd. ("Check-Cap") (NASDAQ: CHEK) shareholders to VOTE AGAINST  the Keystone Dental and FOR the Symetryx slate of highly qualified and independent director nominees.

TORONTO , Dec. 8, 2023 /PRNewswire/ - Further to its news release of November 28, 2023, Symetryx continues to urge its fellow Check-Cap Ltd. ("Check-Cap") (NASDAQ: CHEK) shareholders to VOTE AGAINST  the Keystone Dental and FOR the Symetryx slate of highly qualified and independent director nominees.

TORONTO , Dec. 5, 2023 /PRNewswire/ - Today, Symetryx Corporation ("Symetryx") once again encourages our fellow shareholders of Check-Cap Ltd. ("Check-Cap") (NASDAQ: CHEK) to review the news release issued by Yoav Kimchy, PhD, the Founder and former Chief Technology Officer, and shareholder, of Check-Cap, who has stated in an open letter to his fellow shareholders that the value of the Intellectual Property of Check-Cap was, in essence, disregarded and assigned no monetary value when valuing the Keystone Dental transaction.

Recommends Fellow Shareholders Vote AGAINST Keystone Transaction & the Check-Cap Board Nominees - Further Recommends a Vote FOR the Symetryx Slate of Director Candidates Cites Unrealistic and Aggressive Valuation of Keystone Used to Justify the Merger and Troubling Cash Burn by Check-Cap Board & Management TORONTO , Nov. 28, 2023 /PRNewswire/ - Symetryx, a holder of 5.6% of Check-Cap Ltd. (NASDAQ: CHEK) shares, today issued the following open letter to shareholders.

Q3 revenue increased 18.9% year-over-year to $16.8M, including $11.9M from the U.S. Check-Cap shareholders to vote on proposed Business Combination Agreement with Keystone Dental at Annual General Meeting on Monday, December 18th, 2023 IRVINE, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Keystone Dental Holdings (“Keystone Dental” or the “Company”), a pioneer in dental implant technology, announced today financial results and provided a corporate update for the third quarter and nine months ended September 30, 2023.

Check-Cap shareholders to vote on proposed Business Combination Agreement with Keystone Dental at Annual  General Meeting on Monday, December 18 th ISFIYA, Israel , Nov. 27, 2023 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), today announced financial results and provided a corporate update for the third quarter and nine months ended September 30, 2023.

Proposed business combination to create a Nasdaq-listed medical device company focused on advancing the commercial execution and market development of Keystone's comprehensive portfolio of implants, arches and other tooth replacement solutions